Astellas Pharma Sells Grand Island, N.Y. Plant to APP Pharmaceuticals In Consolidation Move
This article was originally published in PharmAsia News
Executive Summary
TOKYO - Astellas Pharma said Sept. 5 it had sold its Grand Island, N.Y. plant that manufactures atopic dermatitis treatment Protopic (tacrolimus) to APP Pharmaceuticals of Schaumburg, Ill